The effect of Metformin on fibrocystic breast disease in women with insulin resistance
https://doi.org/10.17650/1994-4098-2018-14-3-19-24
Abstract
A little studied question is the development mechanism, timely diagnostics, treatment and prevention of the fibrocystic breast disease at patients with insulin resistance. One of the possible perspective directions of pathogenetic impact on tissues of a mammary gland at the mastopathy associated with a giperinsulinemiya and insulin resistance is use of metformin. Now clinical trials on use of metformin at cancer of mammary glands continue. Data on use of medicines of this group at patients with fibrocystic breast disease in domestic and foreign literature are absent. Objective: assessment of influence of metformin on clinical displays of fibrocystic breast disease and ultrasonic characteristics of a parenchyma of mammary glands at patients with insulin resistance.Materials and methods. As therapy of fibrocystic breast disease patients received metformin in a dose of 1500 mg a day. Dynamic control of a clinical picture of a disease and ultrasonic indicators of a parenchyma of a mammary gland carried out in 3 and 6 months from the beginning of therapy. Results and conclusion. In 6 months of therapy there was a reliable decrease in frequency of a mastalgiya, change of an ultorasound picture of mammary glands: echogenicity of a parenchyma of mammary glands – became sredeny in 95,9% of cases, there was a reliable reduction of thickness of a parenchyma of mammary glands (from 15.5 mm to 10. 5 mm) and diameter of lacteal channels (from 1.7 mm to 0.9 mm). The obtained data on positive influence of metformin on the clinical course of mastopathy and structural changes of a parenchyma of mammary glands at patients with fibrocystic breast disease and insulin resistance allow to consider similar approach as the perspective direction of pathogenetic influence at such pathological association.
About the Authors
E. V. Musina
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation
3 Mendeleevskaya liniya, Saint-Petersburg 199034
Competing Interests: The author declares no conflict of interest.
Russian Federation
3 Mendeleevskaya liniya, Saint-Petersburg 199034
Competing Interests: The author declares no conflict of interest.
I. Y. Kogan
The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott
Russian Federation
3 Mendeleevskaya liniya, Saint-Petersburg 199034
Competing Interests: The author declares no conflict of interest.
Russian Federation
3 Mendeleevskaya liniya, Saint-Petersburg 199034
Competing Interests: The author declares no conflict of interest.
References
1. Silvera S.A., Rohan T.E. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res Treat. 2008;110(3):397–409. DOI: 10.1007/s10549-007-9740-3.
2. Plu-Bureau G., Lê M.G., Sitruk-Ware R., Thalabard J.C. Cyclical mastalgia and breast cancer risk: result of a French cohort study Cancer Epidemiol Biomarkers Prev 2006;15:1229–31. DOI: 10.1158/1055-9965.EPI-05-0745.
3. Коган И.Ю., Мясникова М.О., Мусина Е.В. Прогестерон в лечении мастопатии. Ред. Э.К. Айламазян. СПб., 2012. 68 с. [Kogan I.Ju, Mjasnikova M.O., Musina E.V. Red. Je.K. Ajlamazjan. Progesterone in the treatment of mastitis. Saint Petersburg, 2012. (In Russ.)].
4. Оhansen D., Stocks T., Jonsson H. et al. Metabolic factors and the risk of pancreatic cancer: a prospective analysis of almost 580,000 men and women in the Metabolic Syndrome and Cancer Project. Cancer Epidemiol Biomarkers Prev 2010;19(9):2307–17. DOI: 10,1158/1055-9965.EPI-10-0234.
5. Jiralerspong S., Gonzalez-Angulo A.M., Hung M.C. Expanding the arsenal: metformin for the treatment of triple-negative breast cancer? Cell Cycle 2009;8(17):2681. DOI: 10,4161/сс.8.17.9647.
6. Goodwin P.J., Pritchard K.I. Fasting insulin and outcome in early-stage breast cancer: results of prospective cohort study. J Clin Oncol 2002;20:42–51. DOI: org/10.1200/JCO.2002.20.1.42.
7. Schwartz I.S., Strauchen J.A. Lymphocytic mastopathy: an autoimmune disease of the breast? Am J Clin Pathol 1990;93:725–30.
8. Chan C.L., Ho R.S., Shek T.W., Kwong A. Diabetic mastopathy. Breast J 2013;19:533–8. DOI: 10.1111 / tbj.12158.
9. Dorokhova O., Fineberg S., Koenigsberg T., Wang Y. Diabetic mastopathy, a clinicopathological correlation of 34 cases. Pathol Int 2012;62:660–4. DOI: 10.1111/j.1440-1827.2012.02853.
10. Pereira M.A., de Magalhaes A.V., da Motta L.D. et al. Fibrous mastopathy: clinical, imaging, and histopathologic findings of 31 cases. J Obstet Gynaecol Res 2010;36:326–35. DOI: 10.1111/j.1447-0756.2009.01146.x.
11. Vigneri P., Frasca F., Sciacca L. et al. Diabetes and cancer. Endocr Relat Cancer 2009;16(4): 1103–23. DOI: 10.1677/ERC-09-0087.
12. Gonzalez-Angulo A.M., Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 2010;16(6):1695–700. DOI: 10.1158/1078-0432.CCR-09-1805.
13. Boyd D.B. Insulin and cancer. Integr Cancer Ther 2003;2(4):315–29. DOI: 10.1177/1534735403259152.
14. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4(8):579–91. DOI: 10.1038/nrc1408.
15. Evans J.M., Donnelly L.A., EmslieSmith A.M. et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330(7503):1304–5. DOI: 10,1136 / bmj.38415.708634.F7.
16. Heckman-Stoddard B.M., Decensi A., Sahasrabuddhe V.V., Ford L. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia 2017;60:1639–47. DOI: 10.1007/s00125-017-4372-6 32.
17. Ben Sahra I., Marchand-Brustel Y., Tanti J. et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092–9. DOI: 10.1158/1535-7163.MCT-09-1186.
18. Zhang T., Guo P., Zhan Y. et al. The antidiabetic drug metformin inhibits the proliferation of bladder cancer cells in vitro and in vivo. Int J Mol Sci 2013;14:2403–618. DOI: 10,3390 / ijms141224603.
19. Liu B., Fan Z., Edgerton S.M. et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell cycle 2009;8:2031–40. DOI: 10.4161/cc.8.13.8814.
20. Gadducci A., Biglia N., Tana R. et al. Metformin use and gynecological cancers: a novel treatment option emerging from drug repositioning. Crit Rev Oncol Hematol 2016;105:73–83. DOI: 10.1016/j.critrevonc.2016.06.006.
21. Zhou G., Myers R., Li Y., Chen Y. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108(8):1167–74. DOI: 10.1172/JCI13505.
22. Janzer A., German N.J., Gonzalez-Herrera K.N. et al. Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells. Proc Natl Acad Sci USA 2014;111(29):10574–9. DOI: 10.1073/pnas.1409844111.
23. Bao B., Azmi A.S., Ali S. et al. Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Ann Transl Med 2014; 2(6):59. DOI: 10.3978/j.issn.2305-5839.2014.06.05.
24. Falah R.R., Talib W.H., Shbailat S.J. Combination of metformin and curcumin targets breast cancer in mice by angiogenesis inhibition, immune system modulation and induction of p53 independent apoptosis. Ther Adv Med Oncol 2017;9(4):235–52. DOI: 10.1177/1758834016687482.
Review
For citations:
Musina E.V., Kogan I.Y. The effect of Metformin on fibrocystic breast disease in women with insulin resistance. Tumors of female reproductive system. 2018;14(3):19-24. (In Russ.) https://doi.org/10.17650/1994-4098-2018-14-3-19-24
Views:
3473
Email this article 